Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000935836-24-000149
Filing Date
2024-02-13
Accepted
2024-02-13 18:38:35
Documents
1

Document Format Files

Seq Description Document Type Size
1 kros13ga2024.htm SC 13G/A 40742
  Complete submission text file 0000935836-24-000149.txt   42294
Mailing Address 350 MADISON AVENUE 20TH FLOOR NEW YORK NY 10017
Business Address 350 MADISON AVENUE 20TH FLOOR NEW YORK NY 10017 2127166576
ALKEON CAPITAL MANAGEMENT LLC (Filed by) CIK: 0001230239 (see all company filings)

EIN.: 134200093 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A

Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Subject) CIK: 0001664710 (see all company filings)

EIN.: 811173868 | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-91484 | Film No.: 24630803
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)